Oruka Therapeutics, Inc. 10-Q

ITEM 5. OTHER INFORMATION Not applicable . 47 ITEM 6. EXHIBITS EXHIBIT INDEX The following documents are filed as part of this quarterly report on Form 10-Q. The Company will furnish a copy of any exhibit listed to requesting stockholders upon payment of the Company’s reasonable expenses in furnishing those materials. Incorporated by Reference (1) Exhibit No. Description Form Filing Date Number Filed Herewith 3.1 Amended and Restated Certificate of Incorporation of the Registrant, as amended . 10-K 3/27/2009 3.1 3.1(a) Certificate of Amendment to Restated Certificate of Incorporation . 8-K 3/5/2013 5.1 3.1(b) Certificate of Amendment to Restated Certificate of Incorporation . 8-K 9/3/2015 3.1 3.1(c) Certificate of Amendment to Restated Certificate of Incorporation . 8-K 4/3/2019 3.1 3.2 Amended and Restated Bylaws of the Registrant, as amended . 8-K 6/28/2021 3.1 4.1 Reference is made to Exhibits 3.1, 3.1(a), 3.1(b) and 3.2 4.2 Form of Common Stock Certificate . 10-Q 5/8/2019 4.2 10.1 Amendment No. 1 to Capital on Demand TM Sales Agreement, dated April 6, 2021, by and between ARCA biopharma, Inc. and JonesTrading Institutional Services LLC . 8-K 4/6/2021 10.1 10.2 (2) Employment Agreement, dated April 21, 2021, by and between ARCA biopharma, Inc. and C. Jeff Dekker . 10-Q 5/11/2021 10.1 10.3 (3) Assignment Agreement for Patent Rights, dated July 1, 2021, by and between ARCA biopharma, Inc. and University Medical Center of the Johannes Gutenberg University Mainz . X 31.1 Certification of Principal Executive Officer pursuant to Rule 13a-14(a) or 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 . X 31.2 Certification of Principal Financial Officer pursuant to Rule 13a-14(a) or 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 . X 32.1 Certification of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. sec. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 . X 101.INS Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document X 101.SCH Inline XBRL Taxonomy Extension Schema Document (filed electronically herewith) X 48 Incorporated by Reference (1) Exhibit No. Description Form Filing Date Number Filed Herewith 101.CAL Inline XBRL Taxonomy Extension Calculation Linkbase Document (filed electronically herewith) X 101.LAB Inline XBRL Taxonomy Extension Label Linkbase Document (filed electronically herewith) X 101.PRE Inline XBRL Taxonomy Extension Presentation Linkbase Document (filed electronically herewith) X 101.DEF Inline XBRL Taxonomy Extension Definition Linkbase Document (filed electronically herewith) X 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). (1) The SEC file number for all items incorporated by reference herein from reports on Forms 10-K, 10-Q and 8-K is 000-22873. (2) Indicates management contract or compensatory plan or arrangement. (3) Schedules have been omitted from this filing pursuant to Item 601(b)(2) of Regulation S-K. ARCA agrees to furnish supplementally a copy of any omitted schedule to the SEC upon its request; provided, however, that the Company may request confidential treatment pursuant to Rule 24b-2 of the Exchange Act for any schedule so furnished. Certain portions of the exhibit, identified by the mark, “[*],” have been omitted because such portions contained information that is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. 49 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ARCA biopharma, Inc. (Registrant) By: /s/ C. Jeffrey Dekker C. Jeffrey Dekker Chief Financial Officer (Principal Financial and Accounting Officer) Dated: August 4, 2021 50